Author: Barbui, Tiziano; Vannucchi, Alessandro Maria; Alvarez-Larran, Alberto; Iurlo, Alessandra; Masciulli, Arianna; Carobbio, Alessandra; Ghirardi, Arianna; Ferrari, Alberto; Rossi, Giuseppe; Elli, Elena; Andrade-Campos, Marcio Miguel; Kabat, Mercedes Gasior; Kiladjian, Jean-Jaques; Palandri, Francesca; Benevolo, Giulia; Garcia-Gutierrez, Valentin; Fox, Maria Laura; Foncillas, Maria Angeles; Morcillo, Carmen Montoya; Rumi, Elisa; Osorio, Santiago; Papadopoulos, Petros; Bonifacio, Massimiliano; Cervantes, Keina Susana Quiroz; Serrano, Miguel Sagues; Carreno-Tarragona, Gonzalo; Sobas, Marta Anna; Lunghi, Francesca; Patriarca, Andrea; Elorza, Begona Navas; Angona, Anna; Mazo, Elena Magro; Koschmieder, Steffen; Ruggeri, Marco; Cuevas, Beatriz; Hernandez-Boluda, Juan Carlos; Abadia, Emma Lopez; Cirici, Blanca Xicoy; Guglielmelli, Paola; Garrote, Marta; Cattaneo, Daniele; Daffini, Rosa; Cavalca, Fabrizio; Bellosillo, Beatriz; Benajiba, Lina; Curto-Garcia, Natalia; Bellini, Marta; Betti, Silvia; De Stefano, Valerio; Harrison, Claire; Rambaldi, Alessandro
Title: High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib Cord-id: x1yrvgvn Document date: 2021_1_7
ID: x1yrvgvn
Snippet: We report the clinical presentation and risk factors for survival in 175 patients with myeloproliferative neoplasms (MPN) and COVID-19, diagnosed between February and June 2020. After a median follow-up of 50 days, mortality was higher than in the general population and reached 48% in myelofibrosis (MF). Univariate analysis, showed a significant relationship between death and age, male gender, decreased lymphocyte counts, need for respiratory support, comorbidities and diagnosis of MF, while no
Document: We report the clinical presentation and risk factors for survival in 175 patients with myeloproliferative neoplasms (MPN) and COVID-19, diagnosed between February and June 2020. After a median follow-up of 50 days, mortality was higher than in the general population and reached 48% in myelofibrosis (MF). Univariate analysis, showed a significant relationship between death and age, male gender, decreased lymphocyte counts, need for respiratory support, comorbidities and diagnosis of MF, while no association with essential thrombocythemia (ET), polycythemia vera (PV), and prefibrotic-PMF (pre-PMF) was found. Regarding MPN-directed therapy ongoing at the time of COVID-19 diagnosis, Ruxolitinib (Ruxo) was significantly more frequent in patients who died in comparison with survivors (p = 0.006). Conversely, multivariable analysis found no effect of Ruxo alone on mortality, but highlighted an increased risk of death in the 11 out of 45 patients who discontinued treatment. These findings were also confirmed in a propensity score matching analysis. In conclusion, we found a high risk of mortality during COVID-19 infection among MPN patients, especially in MF patients and/or discontinuing Ruxo at COVID-19 diagnosis. These findings call for deeper investigation on the role of Ruxo treatment and its interruption, in affecting mortality in MPN patients with COVID-19.
Search related documents:
Co phrase search for related documents- acute phase and additional information: 1
- acute phase and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35
- acute phase and logistic regression model: 1, 2, 3, 4, 5
- acute phase and low number: 1, 2
- acute phase and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- acute phase and lymphocyte ratio: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- additional information and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- additional information and logistic regression model: 1, 2, 3
- additional information and low number: 1, 2, 3, 4, 5, 6
- additional information and lymphocyte count: 1, 2
- admission respiratory support and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8
- admission respiratory support and logistic regression model: 1, 2, 3
- admission respiratory support and lymphocyte count: 1, 2
- logistic regression and low number: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- logistic regression and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- logistic regression and lymphocyte ratio: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- logistic regression model and low number: 1, 2, 3
- logistic regression model and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31
- logistic regression model and lymphocyte ratio: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28
Co phrase search for related documents, hyperlinks ordered by date